Pasar al contenido principal

MODULACION DEL ENVEJECIMIENTO Y LA NEURODEGENERACION POR MOLECULAS PEQUEÑAS INHIBIDORAS DE PROTEINA QUINASAS

PID2019-105600RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Aging, NRF2, and TAU: A Perfect Match for Neurodegeneration?

  • Brackhan, Mirjam
  • Arribas-Blázquez, Marina
  • Lastres-Becker, Isabel
Although the trigger for the neurodegenerative disease process is unknown, the relevance of aging stands out as a major risk for the development of neurodegeneration. In this review, we highlighted the relationship between the different cellular mechanisms that occur as a consequence of aging and transcription factor nuclear factor erythroid-2-related factor 2 (NRF2) and the connection with the TAU protein. We focused on the relevance of NRF2 in the main processes involved in neurodegeneration and associated with aging, such as genomic instability, protein degradation systems (proteasomes/autophagy), cellular senescence, and stem cell exhaustion, as well as inflammation. We also analyzed the effect of aging on TAU protein levels and its aggregation and spread process. Finally, we investigated the interconnection between NRF2 and TAU and the relevance of alterations in the NRF2 signaling pathway in both primary and secondary tauopathies. All these points highlight NRF2 as a possible therapeutic target for tauopathies., This work was supported by Ministerio de Ciencia e Innovación, Spain (MINECO) (PID2019-105600RB-I00 to I.L.-B.), Fundación Tatiana Pérez de Guzmán el Bueno (2021/00072/001 to I.L.-B.), Biomedical Research Networking Center on Neurodegenerative Diseases ISCiii CIBERNED (CB06/05/0089 to I.L.-B.). M.B. received funding from the Instituto de Salud Carlos III (IHMC22/00032)., Peer reviewed